Microba Life Sciences Ltd (MAP)

Currency in AUD
0.09
0.00(0.00%)
Closed·
MAP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.090.09
52 wk Range
0.070.30
Key Statistics
Bid/Ask
0.08 / 0.09
Prev. Close
0.09
Open
0.09
Day's Range
0.09-0.09
52 wk Range
0.07-0.3
Volume
346.79K
Average Vol. (3m)
572.51K
1-Year Change
-65.3846%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MAP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.21
Upside
+133.33%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Microba Life Sciences Ltd Company Profile

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Microba Life Sciences Ltd Earnings Call Summary for Q2/2026

  • Microba reported 90% YoY growth in core test volume with an annualized run rate exceeding 21,300 tests, driving a 5.88% stock increase.
  • The company reduced operating expenditure while its Microbiome Explorer product accounted for 55% of total revenue, replacing over AUD 1.6 million in legacy product revenue.
  • Microba is targeting over 24,000 tests for FY2026 with revenue forecasts of $13.66 million, increasing to $18.95 million for FY2027.
  • Strategic partnerships with major diagnostic companies strengthen Microba's position in the clinical microbiome testing market, estimated at over $100 billion.
  • The company is advancing toward regional break-even milestones in Australia and UK while pursuing therapeutics partnering opportunities.
Last Updated: 01/28/2026, 09:02 PM
Read Full Transcript
Microba Life Sciences investor slides for Q2/2026
Microba Q2 FY26 slides
Last Update: Jan 29, 2026
See full investor slides

Compare MAP to Peers and Sector

Metrics to compare
MAP
Peers
Sector
Relationship
P/E Ratio
−3.7x16.9x−0.6x
PEG Ratio
−0.12−0.010.00
Price / Book
1.7x1.5x2.6x
Price / LTM Sales
3.5x1.2x3.4x
Upside (Analyst Target)
133.3%20.5%44.9%
Fair Value Upside
Unlock19.6%6.3%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.21
(+133.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Oct 27, 2025
EPS / Forecast
-- / --
Revenue / Forecast
3.60M / --
EPS Revisions
Last 90 days

MAP Income Statement

FAQ

What Is the Microba Life Sciences (MAP) Stock Price Today?

The Microba Life Sciences stock price today is 0.09

What Stock Exchange Does Microba Life Sciences Trade On?

Microba Life Sciences is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Microba Life Sciences?

The stock symbol for Microba Life Sciences is "MAP."

What Is the Microba Life Sciences Market Cap?

As of today, Microba Life Sciences market cap is 54.20M.

What Is Microba Life Sciences's Earnings Per Share (TTM)?

The Microba Life Sciences EPS (TTM) is -0.03.

When Is the Next Microba Life Sciences Earnings Date?

Microba Life Sciences will release its next earnings report on Mar 04, 2026.

From a Technical Analysis Perspective, Is MAP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Microba Life Sciences Stock Split?

Microba Life Sciences has split 0 times.

What is the current trading status of Microba Life Sciences (MAP)?

As of Feb 02, 2026, Microba Life Sciences (MAP) is trading at a price of 0.09, with a previous close of 0.09. The stock has fluctuated within a day range of 0.09 to 0.09, while its 52-week range spans from 0.07 to 0.30.

What Is Microba Life Sciences (MAP) Price Target According to Analysts?

The average 12-month price target for Microba Life Sciences is AUD0.21, with a high estimate of AUD0.29 and a low estimate of AUD0.13. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +133.33% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.